Answers are grounded in this paper and cite their sources.
Review highlights antiarrhythmic drugs and emerging pharmacological targets for arrhythmias, suggesting future treatment innovations.
With a significant impact on morbidity and mortality rates worldwide, arrhythmias are a growing global health concern. The most common sustained arrhythmia, atrial fibrillation (AF), affects approximately 2% of the general population, with its prevalence increasing with age. Although significant advancements have been made in non-pharmacological therapies, such as catheter ablation and implantable devices, the basis of arrhythmia management remains antiarrhythmic drugs (AADs). Yet the development of safer and more effective AADs has not kept pace with the increasing burden of arrhythmias. This article aims to briefly explore the current landscape of antiarrhythmic treatment, emerging pharmacological targets, and the potential for innovative drug therapies to reshape clinical practice.
No takes yet. Share an insight, caveat, or question.
Totolici et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: